Report of Foreign Issuer (6-k)
09 Abril 2018 - 5:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: April 2018 (Report No.
2)
Commission File Number 001-35932
ARCTURUS THERAPEUTICS LTD.
(Translation of Registrant’s name
into English)
10628 Science Center Drive, Suite 200
San Diego, California 92121
(Address of Principal Executive Office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
On April 8, 2018, Arcturus Therapeutics
Ltd. (the “Company”) announced that, upon the recommendation of the Executive Committee of the Board of Directors of
the Company (the “Board”), the Board approved postponing the Extraordinary General Meeting of Shareholders (EGM) previously
scheduled for May 7, 2018. The press release is attached hereto as Exhibit 99.1.
This Form 6-K, excluding
Exhibit 99.1, is incorporated by reference into the Registration Statements on Form F-3 (File No. 333- 209960) and Form S-8 (File
No. 333-194875, File No. 333-202394, File No. 333-209947, File No. 333-217556 and File No. 333-221830) of the Company, filed with
the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not
superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
ARCTURUS THERAPEUTICS LTD.
|
|
|
|
|
|
|
|
|
Date: April 9, 2018
|
By:
|
/s/ Mark Herbert
|
|
|
Name:
|
Mark Herbert
|
|
|
Title:
|
Interim President
|
|
Exhibit Index
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release issued by the Company on April 8, 2018, titled “Arcturus Therapeutics Issues Statement Regarding Timing of Extraordinary General Meeting of Shareholders.”
|
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024